CSPC Pharmaceutical Group’s Stock Price Dips to 7.38 HKD, Recording a 4.40% Plunge

CSPC Pharmaceutical Group (1093)

7.38 HKD -0.34 (-4.40%) Volume: 157.59M

CSPC Pharmaceutical Group’s stock price is currently at 7.38 HKD, experiencing a decline of 4.40% this trading session with a trading volume of 157.59M. Despite today’s decline, the stock has shown a strong performance with a Year-to-Date (YTD) increase of 53.97%, highlighting its robust market presence.

Latest developments on CSPC Pharmaceutical Group

Today, CSPC Pharmaceutical Group Limited (HKG:1093) saw fluctuations in its stock price following the release of its third-quarter financial report. The company reported a revenue decline of 7.1% year-over-year, attributed to industry challenges and strategic shifts. Despite this, individual investors still hold a significant 42% ownership in the company, while institutions hold 26%. Investors are now questioning the long-term viability of CSPC Pharmaceutical Group stock, comparing it with market leaders and evaluating its potential for future growth.

CSPC Pharmaceutical Group on Smartkarma

Analysts on Smartkarma, such as Tina Banerjee, are closely following the coverage of CSPC Pharmaceutical Group. In a recent report titled “CSPC Pharma (1093 HK): Finished Drugs Drag 1H25; 2H25 Expected To End with More Licensing Deals,” Banerjee notes a drop of 18.5% YoY in 1H25 revenue due to lower finished drug sales. However, the future looks promising with upcoming collaborations and expansion into the high-end market. The company aims to achieve competitive differentiation and higher prices through these strategic moves.

Another report by Tina Banerjee, titled “CSPC Pharmaceutical (1093 HK): Finished Drugs Drag 1Q25; Out Licensing And New Launches To Be Key,” highlights a 22% YoY drop in 1Q25 revenue, with stable operating margins. The focus on out licensing and new launches for pipeline products is expected to improve future revenue visibility. Despite challenges in finished drug sales, CSPC Pharmaceutical Group remains optimistic about its growth prospects through strategic collaborations and product launches.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for CSPC Pharmaceutical Group, the company seems to have a positive long-term outlook. With high scores in Dividend and Value, investors may find CSPC Pharmaceutical Group to be a promising investment option. Additionally, the company’s strong scores in Resilience indicate its ability to withstand economic downturns and challenges.

While CSPC Pharmaceutical Group may not have the highest score in Growth and Momentum, its overall outlook appears to be stable and reliable. As a manufacturer and seller of pharmaceutical products, including vitamin C, antibiotics, and generic drugs, the company plays a crucial role in the healthcare industry. Furthermore, its involvement in the development of innovative drugs and antibiotics suggests potential for future growth and expansion.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma